Clinical Trials Browser

Interventional × liposomal doxorubicin × Breast × Clear all

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04243616 2025-09-05

CemiHALT

Phase 2 Active not recruiting

Invasive Breast Cancer

NCT05029999 2025-08-13

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT05567601 2025-06-05

Doxil/Caelyx BE Study

Phase 1 Completed

BreastGynecologicPlasma cellSarcoma

AIDS-related Kaposi sarcoma, Breast Neoplasms, Multiple Myeloma, Ovarian Neoplasms

NCT03971409 2025-05-02

InCITe

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02488564 2025-02-03

met-HEReMYTA

Phase 2 Completed

HER-2 Positive Breast Cancer

NCT05748834 2025-01-31

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

Phase 2 Recruiting

HER2-negative Breast Cancer

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06653972 2024-10-23

EASOVCWDITHABC

Phase 2 Not yet recruiting

Her2-negative Metastatic Breast Cancer

NCT03164993 2024-10-15

ALICE

Phase 2 Completed

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT03409198 2024-10-15

ICON

Phase 2 Completed

Breast Neoplasms, Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1 Completed

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT04244552 2023-12-29

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03712956 2023-09-21

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Phase 2 Unknown

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Phase 2 Terminated

3 enrolled 6 charts

Breast Neoplasms

NCT00258960 2023-04-04

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Phase 2 Completed

49 enrolled 16 charts

Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Phase 2 Active not recruiting

62 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Phase 3 Completed

1,925 enrolled 19 charts

Breast Neoplasms

NCT00128778 2023-03-06

Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

Phase 4 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT05386524 2023-02-16

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Phase 2 Unknown

Breast Neoplasms

NCT05656079 2022-12-19

easy laugh

Phase NA Unknown

Breast Neoplasms

NCT00976131 2022-10-17

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT05346107 2022-04-26

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03071926 2022-04-20

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

Phase 2 Unknown

Advanced Breast Cancer

NCT05302336 2022-04-14

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Phase 4 Unknown

Breast Neoplasms

NCT05097248 2021-10-28

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Phase 2 Unknown

Breast Neoplasms

NCT00442260 2021-01-22

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

2 enrolled 1 chart

Breast Neoplasms

NCT03933319 2020-07-08

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer

NCT03994107 2020-01-22

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT01935492 2020-01-18

Stop&Go

Phase 3 Completed

Breast Neoplasms

NCT00687440 2018-07-03

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Phase 2 Completed

27 enrolled 5 charts

Breast Neoplasms

NCT02331251 2018-07-02

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Phase 1/2 Terminated

BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT02953184 2017-12-29

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Phase 2 Unknown

Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Genetic Predisposition to Disease

NCT00563953 2017-10-12

CAPRICE

Phase 2 Completed

Breast Neoplasms, Heart Diseases, Neoplasms

NCT00331552 2017-07-26

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed

30 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT03221881 2017-07-19

Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer

Phase NA Completed

Breast Neoplasms